Ribas Núria, García-García Cosme, Meroño Oona, Recasens Lluís, Pérez-Fernández Silvia, Bazán Víctor, Salvatella Neus, Martí-Almor Julio, Bruguera Jordi, Elosua Roberto
Cardiology Department, Hospital del Mar, Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
BMC Cardiovasc Disord. 2017 Feb 7;17(1):54. doi: 10.1186/s12872-017-0493-6.
The AMI code is a regional network enhancing a rapid and widespread access to reperfusion therapy (giving priority to primary angioplasty) in patients with acute ST-segment elevation myocardial infarction (STEMI). We aimed to assess the long-term control of conventional cardiovascular risk factors after a STEMI among patients included in the AMI code registry.
Four hundred and fifty-four patients were prospectively included between June-2009 and April-2013. Clinical characteristics were collected at baseline. The long-term control of cardiovascular risk factors and cardiovascular morbidity/mortality was assessed among the 6-months survivors.
A total of 423 patients overcame the first 6 months after the STEMI episode, of whom 370 (87%) underwent reperfusion therapy (363, 98% of them, with primary angioplasty). At 1-year follow-up, only 263 (62%) had adequate blood pressure control, 123 (29%) had LDL-cholesterol within targeted levels, 126/210 (60%) smokers had withdrawn from their habit and 40/112 (36%) diabetic patients had adequate glycosylated hemoglobin levels. During a median follow-up of 20 (11-30) months, cumulative mortality of 6 month-survivors was 6.1%, with 9.9% of hospital cardiovascular readmissions. The lack of assessment of LDL and HDL-cholesterol were significantly associated with higher mortality and cardiovascular readmission rates.
Whereas implementation of the AMI code resulted in a widespread access to rapid reperfusion therapy, its long-term therapeutic benefit may be partially counterbalanced by a manifestly suboptimal control of cardiovascular risk factors. Further efforts should be devoted to secondary prevention strategies after STEMI.
AMI代码是一个区域网络,旨在提高急性ST段抬高型心肌梗死(STEMI)患者快速广泛获得再灌注治疗(优先进行直接经皮冠状动脉腔内血管成形术)的机会。我们旨在评估AMI代码注册研究中STEMI患者常规心血管危险因素的长期控制情况。
2009年6月至2013年4月期间前瞻性纳入了454例患者。在基线时收集临床特征。对6个月幸存者的心血管危险因素长期控制情况及心血管发病率/死亡率进行评估。
共有423例患者度过了STEMI发作后的前6个月,其中370例(87%)接受了再灌注治疗(其中363例,98%接受直接经皮冠状动脉腔内血管成形术)。在1年随访时,只有263例(62%)血压控制良好,123例(29%)低密度脂蛋白胆固醇水平达标,126/210例(60%)吸烟者戒烟,40/112例(36%)糖尿病患者糖化血红蛋白水平达标。在中位随访20(11 - 30)个月期间,6个月幸存者的累积死亡率为6.1%,心血管疾病再入院率为9.9%。未评估低密度脂蛋白和高密度脂蛋白胆固醇与较高的死亡率和心血管疾病再入院率显著相关。
尽管AMI代码的实施使患者广泛获得了快速再灌注治疗,但其长期治疗益处可能会被心血管危险因素明显未达最佳控制的情况部分抵消。STEMI后的二级预防策略应进一步加强。